Cara Therapeutics(CARA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CARA Cara Therapeutics

Trading 07-01 14:31:54 EDT

0.2714

+0.0134

+5.19%

High0.2800	Low0.2610	Vol534.79K
Open0.2720	D1 Closing0.2580	Amplitude7.36%
Mkt Cap14.84M	Tradable Cap12.65M	Total Shares54.68M
T/O143.63K	T/O Rate1.15%	Tradable Shares46.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CARA","market":"US","secType":"STK","nameCN":"Cara Therapeutics","latestPrice":0.2714,"timestamp":1719858669201,"preClose":0.258,"halted":0,"volume":534789,"delay":0,"floatShares":46606127,"shares":54675954,"eps":-2.259577,"marketStatus":"Trading","change":0.0134,"latestTime":"07-01 14:31:54 EDT","open":0.272,"high":0.28,"low":0.261,"amount":143631.42628932,"amplitude":0.073643,"askPrice":0.2717,"askSize":110,"bidPrice":0.2713,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-2.259577,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1719864000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":0.258,"preHourTrading":{"tag":"盘前","latestPrice":0.28,"preClose":0.258,"latestTime":"09:19 EDT","volume":7401,"amount":2060.00854992,"timestamp":1719839961954},"postHourTrading":{"tag":"盘后","latestPrice":0.2774,"preClose":0.258,"latestTime":"19:18 EDT","volume":554547,"amount":143323.69084,"timestamp":1719616682230},"volumeRatio":0.310225,"impliedVol":1.6901,"impliedVolPercentile":0.3984},"requestUrl":"/m/hq/s/CARA","defaultTab":"news","newsList":[{"id":"2445014346","title":"Carasent To Supply Ad Curis To Frelsesarmeen","url":"https://stock-news.laohu8.com/highlight/detail?id=2445014346","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445014346?lang=en_us&edition=fundamental","pubTime":"2024-06-24 13:02","pubTimestamp":1719205376,"startTime":"0","endTime":"0","summary":"Carasent ASA :Carasent Group Signs Contract To Supply Ad Curis To Frelsesarmeen.Annual Recurring Revenue From Contract Is Nok 3.3 Million.Contract Also Includes Nok 6 Million Of Consulting Revenue.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CARA","CRIS"],"gpt_icon":0},{"id":"2444211912","title":"Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2444211912","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444211912?lang=en_us&edition=fundamental","pubTime":"2024-06-20 21:14","pubTimestamp":1718889297,"startTime":"0","endTime":"0","summary":"Health care stocks were lower pre-bell Thursday as the Health Care Select Sector SPDR Fund  was down 0.3% and iShares Biotechnology ETF  was recently declining by 0.3%. Jazz Pharmaceuticals  was down more than 3% after saying its investigational therapy suvecaltamide did not meet its primary endpoint in a phase 2b trial evaluating its efficacy and safety in adult patients with essential tremor.PTC Therapeutics  was up over 3% after saying the US Food and Drug Administration has lifted the partial clinical hold on its PTC518 program following favorable interim results from the phase 2 PIVOT-HD study in Huntington's disease patients.Cara Therapeutics  late Tuesday disclosed plans to explore strategic alternatives and lay off 70% of its workforce after discontinuing work on its difelikefalin drug candidate last week for failing to show clinical benefit in pruritus treatment, a nerve disorder. Cara Therapeutics rose past 8% premarket.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","BK4139","LU0320765992.SGD","LU0889565916.HKD","BK4585","BK4007","CARA","BK4533","XLV","PTCT","JAZZ","BK4581","IBB","LU0109394709.USD","BK4588"],"gpt_icon":0},{"id":"2444657894","title":"Cara Therapeutics to Idle 70% Workforce, Explore Alternatives After Scrapping Notalgia Paresthetica Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2444657894","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444657894?lang=en_us&edition=fundamental","pubTime":"2024-06-19 05:11","pubTimestamp":1718745079,"startTime":"0","endTime":"0","summary":"Cara Therapeutics  late Tuesday disclosed plans to explore strategic alternatives and lay off 70% workforce after discontinuing work on its difelikefalin drug candidate last week for failing to show clinical benefit in pruritus treatment, a nerve disorder.The company is expecting to recognize around $2.6 million in one-time charges associated with the job cuts, mostly for termination costs during the current and upcoming quarters this year. The company expects to complete the workforce reduction by the end of June.Cara said previously that it had about $70 million in cash, equivalents and marketable securities on hand at the end of March.Cara shares were up more than 3% in extended trading, after a nearly 5% regular-session decline.Price: 0.2502, Change: +0.01, Percent Change: +3.13","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","CARA"],"gpt_icon":0},{"id":"2444659234","title":"BRIEF-Cara Therapeutics Says Board Approved A Streamlined Operating Plan Exploring Strategic Alternatives Focused On Maximizing Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2444659234","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444659234?lang=en_us&edition=fundamental","pubTime":"2024-06-19 05:03","pubTimestamp":1718744620,"startTime":"0","endTime":"0","summary":"June 18  - Cara Therapeutics Inc   :   * CARA THERAPEUTICS - ON JUNE 14 BOARD APPROVED A STREAMLINED OPERATING PLAN EXPLORING STRATEGIC ALTERNATIVES FOCUSED ON MAXIMIZING SHAREHOLDER VALUE   * CARA THERAPEUTICS -IN CONNECTION WITH STREAMLINED OPERATING PLAN, BOARD OF DIRECTORS APPROVED REDUCTION IN  CO’S WORKFORCE BY APPROXIMATELY 70%   * CARA THERAPEUTICS INC - ANTICIPATES RECOGNIZING ABOUT $2.6 MILLION IN TOTAL CHARGES IN CONNECTION WITH REDUCTION IN FORCE   * CARA THERAPEUTICS INC -COSTS ARE EXPECTED TO BE SUBSTANTIALLY RECOGNIZED IN THE SECOND AND THIRD QUARTER OF 2024   * CARA THERAPEUTICS - APPROVED REDUCTION IN COMPANY'S WORKFORCE BY APPROXIMATELY 70%, WHICH COMPANY EXPECTS TO SUBSTANTIALLY COMPLETE BY JUNE 30, 2024Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARA"],"gpt_icon":0},{"id":"2444465913","title":"Cara Therapeutics to Cut 70% of Workforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2444465913","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444465913?lang=en_us&edition=fundamental","pubTime":"2024-06-19 04:55","pubTimestamp":1718744100,"startTime":"0","endTime":"0","summary":"Cara Therapeutics said it plans to cut about 70% of its workforce due to discontinuing one of its clinical programs.The company on Tuesday said in a filing with the U.S. Securities and Exchange Commission that it expects to incur charges of around $2.6 million in connection with the job cuts, which are expected to be substantially recognized in the second and third quarters.Last week, the commercial-stage biopharmaceutical company said it planned to discontinue its clinical program in notalgia paresthetica, after releasing data that showed oral difelikefalin failed to demonstrate a meaningful clinical benefit at any dose compared to placebo. \"We will be winding down the Phase 2/3 clinical program in notalgia paresthetica and exploring strategic alternatives focused on maximizing shareholder value,\" Chief Executive Christopher Posner said on June 12.Notalgia paresthetica is a chronic condition that causes a localized itch in the upper back.Shares in Cara Therapeutics closed down 4.7% at","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARA","BK4007"],"gpt_icon":0},{"id":"2444912585","title":"Analysts Offer Insights on Healthcare Companies: Cara Therapeutics (CARA) and Disc Medicine (IRON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2444912585","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444912585?lang=en_us&edition=fundamental","pubTime":"2024-06-18 10:10","pubTimestamp":1718676634,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cara Therapeutics (CARA – Research Report) and Dis...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cara-therapeutics-cara-and-disc-medicine-iron?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cara-therapeutics-cara-and-disc-medicine-iron?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","IRON","BK4137","BK4007","BK4139","CARA"],"gpt_icon":0},{"id":"2443819296","title":"Chipotle, McDonald's initiated: Wall Street's top analyst calls","url":"https://stock-news.laohu8.com/highlight/detail?id=2443819296","media":"The Fly","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443819296?lang=en_us&edition=fundamental","pubTime":"2024-06-13 21:51","pubTimestamp":1718286683,"startTime":"0","endTime":"0","summary":"The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades:. Wolfe Research upgraded 3M  to Outperform from Peer Perform with a $125 price target. The company's new CEO Bill Brown \"brings The Right Stuff to 3M,\" providing more confidence in the medium-term earnings outlook, the firm tells investors in a research note.Barclays downgraded NextEra Energy Partners  to Underweight from Equal Weight with a price target of $25, down from $32. With limited debt capacity should the company want to stay within its credit ratings, and an \"extremely high\" payout ratio of 95%, NextEra has limited potential options outside a distribution cut, with a reduction of at least 45% necessary, to pay off its remaining convertible equity portfolio financings, the firm tells investors in a research note.Janney Montgomery Scott downgraded Generac  to Neutral from Buy with a fa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zUit8GQVW5kcaTZHEPMI9Q--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zUit8GQVW5kcaTZHEPMI9Q--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chipotle-mcdonalds-initiated-wall-streets-135123436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["WRB","CARA","LU1244550494.USD","DPZ","SGXZ81514606.USD","BK4227","KMB","MAA","SGXZ99366536.SGD","YUM","JACK","BK4534","WEN","LU0880133367.SGD","LU2133065610.SGD","LU1861220207.SGD","BK4547","PAR","IE00BMG7P587.USD","BK4127","SBUX","LU1267930730.SGD","GNRC","BK4106","ROP","LU0417517546.SGD","LU1718418525.SGD","IE00BSNM7G36.USD","CMG","QSR","NTES","LU0320765059.SGD","PAGS","LU1430594728.SGD","BK4548","WING","SG","LU1880383366.USD","LU2065169927.USD","MMM","BK4532","MCD","LU1861217088.USD","IE00BFSS7M15.SGD","LU1807302812.USD","LU2065171402.SGD","GEV","BK4531","NEP","BK4107"],"gpt_icon":0},{"id":"2443689583","title":"Dow Tumbles Over 100 Points; US Producer Prices Decline In May","url":"https://stock-news.laohu8.com/highlight/detail?id=2443689583","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443689583?lang=en_us&edition=fundamental","pubTime":"2024-06-13 21:45","pubTimestamp":1718286342,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/06/39312852/dow-tumbles-over-100-points-us-producer-prices-decline-in-may","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4192","SQQQ","BK4198","PCOM","QID","TQQQ","BK4583","IONM","MNQmain",".IXIC","QLD","BK4122","BK4161","BK4139","STSS","BURU","BK4007","PSQ","BK4196","CARA","NQmain","BK4539","QQQ","EJH","BRTX"],"gpt_icon":0},{"id":"2443506718","title":"BUZZ-Cara drops on scrapping of neurological condition study, strategic options plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2443506718","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443506718?lang=en_us&edition=fundamental","pubTime":"2024-06-13 18:57","pubTimestamp":1718276270,"startTime":"0","endTime":"0","summary":"** Shares of Cara Therapeutics    fall 20.03% to 54 cents premarket   ** Co late on Wednesday said it will wind down studying its drug for a type of neurological condition after it did not show a meaningful clinical benefit at any dose compared to placebo   ** Adds, will explore strategic alternatives   ** Co was studying oral difelikefalin in adult patients with notalgia paresthetica, a neurological condition that causes intense itching, in a mid-to-late stage trial    ** Brokerage Canaccord Genuity downgrades to hold from buy, cuts PT to $1 from $10   ** Says it is difficult to predict what the results of any upcoming strategic initiatives might be   ** Up to last close, stock down ~9% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARA","BUZZ"],"gpt_icon":0},{"id":"2443150547","title":"Needham Downgrades Cara Therapeutics to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2443150547","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443150547?lang=en_us&edition=fundamental","pubTime":"2024-06-13 18:38","pubTimestamp":1718275135,"startTime":"0","endTime":"0","summary":"(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CARA"],"gpt_icon":0},{"id":"2443055615","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Cara Therapeutics (CARA), Affimed (AFMD) and Ventyx Biosciences (VTYX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2443055615","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443055615?lang=en_us&edition=fundamental","pubTime":"2024-06-13 18:22","pubTimestamp":1718274159,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cara Therapeutics (CARA – Research Report), Affimed (AFMD – Resea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cara-therapeutics-cara-affimed-afmd-and-ventyx-biosciences-vtyx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cara-therapeutics-cara-affimed-afmd-and-ventyx-biosciences-vtyx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CARA","AFMD","BK4137","BK4139","BK4007","VTYX","HCSG"],"gpt_icon":0},{"id":"2443503239","title":"Cara Therapeutics Cut to Hold From Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2443503239","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443503239?lang=en_us&edition=fundamental","pubTime":"2024-06-13 18:18","pubTimestamp":1718273880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CARA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 13, 2024 06:18 ET (10:18 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CARA"],"gpt_icon":0},{"id":"2443550556","title":"H.C. Wainwright downgrades Cara Therapeutics (CARA) to a Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2443550556","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443550556?lang=en_us&edition=fundamental","pubTime":"2024-06-13 18:17","pubTimestamp":1718273857,"startTime":"0","endTime":"0","summary":"Cara Therapeutics (CARA – Research Report) received a Hold rating and price target from H.C. Wainwright analyst Oren Livnat today. The company’s sh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-downgrades-cara-therapeutics-cara-to-a-hold?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-downgrades-cara-therapeutics-cara-to-a-hold?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CARA"],"gpt_icon":0},{"id":"2443625570","title":"Canaccord Genuity Downgrades Cara Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2443625570","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443625570?lang=en_us&edition=fundamental","pubTime":"2024-06-13 17:46","pubTimestamp":1718271974,"startTime":"0","endTime":"0","summary":"Price: 0.5901, Change: -0.09, Percent Change: -13.16","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CARA"],"gpt_icon":0},{"id":"2443783135","title":"U.S. RESEARCH ROUNDUP-Avidity Biosciences, Broadcom, Cara Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2443783135","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443783135?lang=en_us&edition=fundamental","pubTime":"2024-06-13 15:24","pubTimestamp":1718263485,"startTime":"0","endTime":"0","summary":"June 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Avidity Biosciences, Broadcom and Cara Therapeutics, on Thursday","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO","BK4088","LU1670711123.USD","CRL","LU0957808578.USD","LU1244550494.USD","SG9999014898.SGD","LU0056508442.USD","LU1670627923.USD","AVGOP","LU1242518931.SGD","LU0444971666.USD","LU1720051108.HKD","WMB","LU0861579265.USD","LU0070302665.USD","SG9999018865.SGD","CARA","IE00B19Z6F94.USD","LU1670711040.USD","LU2065731478.USD","IE00BD6J9T35.USD","BK4082","AVGO","LU2065732104.USD","TWST","LU0097036916.USD","LU0198837287.USD","LU1242518857.USD","GLW","LU0390134368.USD","IE00BMPRXN33.USD","CELH","LU0820561909.HKD","LU1670710588.SGD","LU0466842654.USD","LU0689472784.USD","LU1642822529.SGD","RNA","LU0820561818.USD","APH","CASY","ENOV","MTH","BK4533","LU0170899867.USD","LU0320765489.SGD","LU1670628061.USD","LU1992135399.USD","LU1670710661.SGD"],"gpt_icon":0},{"id":"2443351341","title":"Cara Therapeutics Halts Trials for Itch Medication Difelikefalin","url":"https://stock-news.laohu8.com/highlight/detail?id=2443351341","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443351341?lang=en_us&edition=fundamental","pubTime":"2024-06-13 06:00","pubTimestamp":1718229602,"startTime":"0","endTime":"0","summary":"Cara Therapeutics (CARA) has provided an update. Cara Therapeutics, Inc. recently announced that their oral medication difelikefalin did not show s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cara-therapeutics-halts-trials-for-itch-medication-difelikefalin?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cara-therapeutics-halts-trials-for-itch-medication-difelikefalin?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CARA","BK4007"],"gpt_icon":0},{"id":"2443594452","title":"Cara Therapeutics to Discontinue Clinical Program to Treat Notalgia Paresthetica Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2443594452","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443594452?lang=en_us&edition=fundamental","pubTime":"2024-06-13 04:24","pubTimestamp":1718223840,"startTime":"0","endTime":"0","summary":"Cara Therapeutics said it is discounting a clinical program to treat patients with notalgia paresthetica on the outcome from the dose-finding part A of its Kourage-1 study.The commercial-stage biopharmaceutical company on Wednesday said it is  disappointed that oral difelikefalin failed to demonstrate a meaningful clinical benefit at any dose compared to placebo during the study.Notalgia paresthetica is a chronic condition that causes a localized itch in the upper back.\"We will be winding down the Phase 2/3 clinical program in notalgia paresthetica and exploring strategic alternatives focused on maximizing shareholder value,\" Chief Executive Christopher Posner said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARA","BK4007"],"gpt_icon":0},{"id":"2443944395","title":"Cara Therapeutics Discontinues NP Program After Drug Study Fails to Show Clinical Benefit -- Shares Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2443944395","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443944395?lang=en_us&edition=fundamental","pubTime":"2024-06-13 04:23","pubTimestamp":1718223800,"startTime":"0","endTime":"0","summary":"Cara Therapeutics  said late Wednesday the results of a trial assessing the efficacy and safety of oral difelikefalin to treat notalgia paresthetica, a nerve disorder, didn't demonstrate meaningful clinical benefit compared to placebo.The company has decided to discontinue its clinical program in notalgia paresthetica.\"We will be winding down the Phase 2/3 clinical program in [notalgia paresthetica] and exploring strategic alternatives focused on maximizing shareholder value,\" said Cara Chief Executive Christopher Posner.The company said, as of March 31, it had about $70 million in cash, cash equivalents, and marketable securities.Cara shares were down more than 15% in after-hours activity.Price: 0.5761, Change: -0.10, Percent Change: -15.22","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CARA","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.caratherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0686},{"period":"1month","weight":-0.5818},{"period":"3month","weight":-0.7165},{"period":"6month","weight":-0.6528},{"period":"1year","weight":-0.9095},{"period":"ytd","weight":-0.6528}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0344},{"period":"3month","weight":0.0404},{"period":"6month","weight":0.145},{"period":"1year","weight":0.2422},{"period":"ytd","weight":0.145}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.067158},{"month":2,"riseRate":0.363636,"avgChangeRate":0.022695},{"month":3,"riseRate":0.545455,"avgChangeRate":0.01829},{"month":4,"riseRate":0.181818,"avgChangeRate":-0.111103},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.001774},{"month":6,"riseRate":0.636364,"avgChangeRate":-0.002947},{"month":7,"riseRate":0.4,"avgChangeRate":0.063213},{"month":8,"riseRate":0.4,"avgChangeRate":-0.005634},{"month":9,"riseRate":0.2,"avgChangeRate":-0.060144},{"month":10,"riseRate":0.5,"avgChangeRate":-0.035975},{"month":11,"riseRate":0.6,"avgChangeRate":0.058974},{"month":12,"riseRate":0.4,"avgChangeRate":-0.091766}],"exchange":"NASDAQ","name":"Cara Therapeutics","nameEN":"Cara Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cara Therapeutics(CARA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cara Therapeutics(CARA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cara Therapeutics,CARA,Cara Therapeutics股票,Cara Therapeutics股票老虎,Cara Therapeutics股票老虎国际,Cara Therapeutics行情,Cara Therapeutics股票行情,Cara Therapeutics股价,Cara Therapeutics股市,Cara Therapeutics股票价格,Cara Therapeutics股票交易,Cara Therapeutics股票购买,Cara Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cara Therapeutics(CARA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cara Therapeutics(CARA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}